Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Rewriting Life

The Rocket Fuel for Biden’s “Cancer Moonshot”? Big Data

The National Cancer Institute hopes a new data-sharing agreement with Foundation Medicine is the first of many.

If Vice President Joe Biden’s Cancer Moonshot is really going to double the pace of progress in preventing, diagnosing, and treating cancer, it’s going need a lot more data. That means it’s probably going to need more data-sharing arrangements like one announced at today’s Cancer Moonshot Summit in Washington, D.C., between the National Cancer Institute and Foundation Medicine, a biotech firm selling tests that sequence tumor genomes.

To speed up advances, Biden has called for more data sharing and collaboration between cancer researchers in academia, industry, and the government. Foundation, which will give the NCI genomic “profiles” of tumors from 18,000 adults, is the first company to contribute to the NCI’s new “Genomic Data Commons,” a public database and analysis platform for cancer genomics. The new data doubles the size of the database, which is crucial to Biden’s project and to President Obama’s Precision Medicine Initiative. It will help researchers study genetic abnormalities seen in many cancers, and it could also help lead to new opportunities for treatment.

Vice President Joe Biden is leading an effort to accelerate cancer research.

Before today, NCI’s database held sequencing information from the tumors of some 14,500 patients with cancer, including clinical data about how they responded to drugs. Large databases like this could help researchers better understand the nature of cancers and locate clues as to why some tumors respond to drugs and others don’t, and why some respond and then relapse.

The information from Foundation isn’t so comprehensive; it will not include information about how patients responded to drugs. Nonetheless, it is a “dramatic” addition to the NCI’s existing data resources, says Louis Staudt, director of the NCI’s Center for Cancer Genomics. The larger the data set, the greater the chance new things will be discovered. “By more than doubling the number of patients, we will vastly increase the explanatory power of the database for understanding cancer,” says Staudt.

The idea of precision medicine is to use as much biological information as possible to make sure that treatments are more precisely tailored to individuals and their diseases. The challenge of doing this for cancer is that it is far from a single disease—there are at least 200 forms and many more subtypes, defined by specific abnormalities in tumor genomes.

Some patients have tumors with abnormalities seen only in an extremely small fraction of people with that kind of cancer, says Staudt, and in some cases there are drugs that work against those rare cancers. There could be similarly uncommon alterations that haven’t yet been found and might represent new targets for drugs. Adding more patients to the NCI’s database increases its power to help discover them.

Staudt hopes the donation by Foundation Medicine will inspire similar moves by other groups with data sets that would be valuable for cancer genomics. The NCI will also be generating its own new data through innovative clinical trials like NCI-MATCH, which is focused on testing targeted therapies on large numbers of patients whose tumors contain specific abnormalities.

Ideally what’s needed is a collection that includes both large amounts of patient sequencing information and detailed clinical information, especially about therapy outcomes, says Clifford Hudis, CEO of the American Society of Clinical Oncology. That means doctors will have to improve their data entry in medical records and the data will have to be readable by computers, he says.

But bringing this type of information together will also be complicated by concerns about patient privacy and laws governing the sharing of such data. And commercial entities aren’t always going to be willing to part with their data. Foundation says it has done so in this case in order to “accelerate” precision medicine. “Maybe this gives us a jump start,” says Hudis.

 

Tech Obsessive?
Become an Insider to get the story behind the story — and before anyone else.

Subscribe today
Vice President Joe Biden is leading an effort to accelerate cancer research.

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Plus.
  • Insider Plus {! insider.prices.plus !}*

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Bimonthly print magazine (6 issues per year)

    Bimonthly digital/PDF edition

    Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

    Special interest publications

    Discount to MIT Technology Review events

    Special discounts to select partner offerings

    Ad-free web experience

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.